Pattern of dyslipidaemia in relation to statin use in patients with type 2 diabetes mellitus attending a tertiary care hospital

Figures & data

Table 1: Characteristics of the study group

Patient characteristics	(n = 200)
Age (years)*	58.9 (11.04)
Gender:
Male	86 (43)
Female	114 (57)
Duration of diabetes:
Less than and equal to 5 years	32 (16)
Between 5 and 10 years	62 (31)
More than 10 years	106 (53)
Weight more than or equal to 100 kg	41 (20.5)
Pre-existent hypertension (SBP > 140 mmHg, DBP > 80 mmHg, or both)	162 (81)
Blood pressure (mmHg): *
SBP	139.5 (20.56)
DBP	77.6 (12.30)
At target blood pressure (< 140/80 mmHg)	71 (43.8) (n = 162)^#
Smoking history:	n = 136^#
Smoker	10 (7.4)
Ex-smoker	6 (4.4)
Established cardiovascular disease:	25 (12.5)
Coronary artery	17 (8.5)
Cerebrovascular	7 (3.5)
Peripheral artery	1 (0.5)
Chronic kidney disease (defines as eGFR < 30 ml/min/1.73 m²)	2 (1)

Results expressed as n (%) except where indicated by an asterisk (*) where reported as mean (standard deviation).

Total number of participants (n) = 200, except where indicated by # (number of participants for whom data were available).

Duration of diabetes, weight, eGFR (estimated glomerular filtration rate), SBP = systolic blood pressure, DBP = diastolic blood pressure, age (years): calculated or measured relative to the subject’s date of visit, percentages are calculated relative to the total number of subjects with data.

Table 2: Description of the lipid profile

Lipid fraction	Minimum (mmol/l)	Maximum (mmol/l)	Median and IQR (mmol/l)
Total cholesterol	1.98	7.20	3.99 (IQR 1.18)
Triglycerides	0.23	8.94	1.31 (IQR 1.1)
HDL-C	0.54	3.07	Men 1.06 (IQR 0.47)
			Women 1.24 (IQR 0.43)
LDL-C	0.69	5.87	2.21 (IQR 1.13)

Figure 1: Lipids at target.

Table 3: Statin therapy according to intensity

Statin intensity	Number on treatment	Percentage
No statin	34	17
Low intensity¹	96	48
Moderate intensity²	56	28
High intensity³	15	7.5

¹Low intensity (simvastatin 10 mg, simvastatin 20 mg, atorvastatin 10 mg).

²Moderate intensity (simvastatin 40 mg, simvastatin 60 mg, atorvastatin 20 mg).

³High intensity (atorvastatin 40 mg, atorvastatin 60 mg, atorvastatin 80 mg, rosuvastatin 20 mg, rosuvastatin 40 mg).

Table 4: Correlation of HBA1C and lipid profile.

Lipid fraction	Correlation coefficient (r)	p-value
Total cholesterol	0.20	<0.01
Triglycerides	0.15	0.03
HDL-C	0.02	0.83
LDL-C	0.19	0.01

Table 5: Breakdown of HBA1C

Category	Median (%)	IQR (%)
Males	8.3	3.3
Females	8.2	3.3
Total cholesterol < 4.5 mmol/l	7.9	2.9
Triglycerides < 1.7 mmol/l	8.1	3.1
HDL-C > 1.0 (men), > 1.2 (women)	8.3	3.4
LDL-C at target	7.7	2.7
Weight ≥ 100 kg	8.2	3.5

Table 6: Weight ≥ 100kg, lipid profile and HBA1C

Gender	Median total cholesterol (mmol/l) (IQR)		Median triglycerides (mmol/l) (IQR)		Median HDL-C (mmol/l) (IQR)		Median LDL-C (mmol/l) (IQR)		Median HBA1C % (IQR)
	< 100 kg	≥ 100 kg	< 100 kg	≥ 100 kg	< 100 kg	≥ 100 kg	< 100 kg	≥ 100 kg	< 100 kg	≥ 100 kg
Male	3.62 (0.90)	4.11 (1.12)	1.24 (0.95)	1.65 (1.74)	1.07 (0.49)	0.98 (0.40)	2.1 (0.81)	2.21 (1.17)	8.3 (3.3)	8.7 (3.2)
Female	4.22 (1.29)	3.89 (0.93)	1.35 (1.03)	1.29 (1.08)	1.26 (0.42)	1.08 (0.42)	2.42 (1.13)	2.15 (0.86)	8.3 (3.3)	8.0 (3.2)

Figure 2: Correlation of controlled/at-target lipids for participants with HBA1C < 7%.